MX2007010962A - Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico. - Google Patents
Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico.Info
- Publication number
- MX2007010962A MX2007010962A MX2007010962A MX2007010962A MX2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A MX 2007010962 A MX2007010962 A MX 2007010962A
- Authority
- MX
- Mexico
- Prior art keywords
- rapamycin
- combination
- myxoma virus
- therapeutic treatment
- cells
- Prior art date
Links
- 241000700562 Myxoma virus Species 0.000 title abstract 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 4
- 229960002930 sirolimus Drugs 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005860 defense response to virus Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65881605P | 2005-03-07 | 2005-03-07 | |
| PCT/CA2006/000315 WO2006094385A1 (en) | 2005-03-07 | 2006-03-06 | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007010962A true MX2007010962A (es) | 2008-03-10 |
Family
ID=36952904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007010962A MX2007010962A (es) | 2005-03-07 | 2006-03-06 | Uso de una combinacion de virus myxoma y rapamicina para tratamiento terapeutico. |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20090035276A1 (https=) |
| EP (2) | EP2388315B1 (https=) |
| JP (2) | JP2008531739A (https=) |
| KR (1) | KR101479093B1 (https=) |
| CN (2) | CN102357104B (https=) |
| AU (1) | AU2006222500B2 (https=) |
| CA (1) | CA2600675C (https=) |
| DK (1) | DK2388315T3 (https=) |
| IL (2) | IL185376A0 (https=) |
| MX (1) | MX2007010962A (https=) |
| NZ (2) | NZ577283A (https=) |
| RU (1) | RU2461630C2 (https=) |
| UA (1) | UA96412C2 (https=) |
| WO (1) | WO2006094385A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090035276A1 (en) | 2005-03-07 | 2009-02-05 | Robarts Research Institute | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
| WO2007143548A2 (en) | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Myxoma virus mutants for cancer treatment |
| JP5748656B2 (ja) * | 2008-05-22 | 2015-07-15 | ジェ イル ファーマシューティカル カンパニー リミテッド | 過剰増殖細胞の腫瘍抑制因子に基づいた腫瘍崩壊ウイルスに対する感受性を判定する方法 |
| US20120100109A1 (en) * | 2010-10-26 | 2012-04-26 | Xiaoliu Zhang | Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors |
| WO2012171007A2 (en) | 2011-06-09 | 2012-12-13 | University Of Florida Research Foundation, Inc. | Methods for treating or preventing graft versus host disease |
| RU2695136C1 (ru) * | 2018-06-19 | 2019-07-22 | Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) | Онколитический способ терапии рака молочной железы. |
| EP3833367A4 (en) | 2018-08-08 | 2022-05-11 | Arizona Board of Regents on behalf of Arizona State University | Method for improved poxvirus yields |
| CA3112788A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| JP2022546985A (ja) * | 2019-09-02 | 2022-11-10 | アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティー | 非許容性の癌に対する腫瘍溶解性ウイルスの感染を改善する方法および組成物 |
| EP4041266A1 (en) * | 2019-10-10 | 2022-08-17 | Arizona Board of Regents on behalf of Arizona State University | Oncolytic virus comprising immunomodulatory transgenes and uses thereof |
| AU2020361622A1 (en) * | 2019-10-10 | 2022-04-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic viruses that express multi-specific immune cell engagers |
| WO2022139440A1 (ko) * | 2020-12-22 | 2022-06-30 | 바이로큐어 주식회사 | 신규한 재조합 믹소마바이러스 및 이의 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| ATE241994T1 (de) | 1996-01-25 | 2003-06-15 | Univ Glasgow | Hsv-mutant-1716 zur behandlung von mesotheliomen |
| EP1003894A2 (en) | 1997-07-18 | 2000-05-31 | Chiron Corporation | Lentiviral vectors |
| US7041654B2 (en) * | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| CN101618049A (zh) | 1997-10-09 | 2010-01-06 | 威尔斯塔特生物公司 | 使用病毒来治疗赘生物 |
| US6264940B1 (en) * | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
| AU6175000A (en) * | 1999-07-12 | 2001-01-30 | Viron Therapeutics, Inc. | Novel myxoma genes for immune modulation |
| BR0015491A (pt) * | 1999-11-12 | 2002-10-15 | Oncolytics Biotech Inc | Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro |
| WO2001087324A1 (en) * | 2000-05-17 | 2001-11-22 | Viron Therapeutics, Inc. | Compositions and methods for promoting immunosuppression |
| MX368013B (es) * | 2001-02-19 | 2019-09-13 | Novartis Ag | Tratamiento de cáncer. |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| KR20120002613A (ko) * | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| JP4800924B2 (ja) * | 2003-03-07 | 2011-10-26 | ロバーツ リサーチ インスティテュート | 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 |
| DE602004004520T2 (de) * | 2003-04-22 | 2007-11-08 | Wyeth | Antineoplastische zusammensetzungen |
| WO2005002607A2 (en) * | 2003-07-07 | 2005-01-13 | Oncolytics Biotech Inc. | Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac |
| US20070207149A1 (en) * | 2004-04-27 | 2007-09-06 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
| US20090035276A1 (en) | 2005-03-07 | 2009-02-05 | Robarts Research Institute | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
-
2006
- 2006-03-06 US US11/908,076 patent/US20090035276A1/en not_active Abandoned
- 2006-03-06 EP EP11174887.7A patent/EP2388315B1/en not_active Expired - Lifetime
- 2006-03-06 KR KR1020077022872A patent/KR101479093B1/ko not_active Expired - Fee Related
- 2006-03-06 CA CA2600675A patent/CA2600675C/en not_active Expired - Fee Related
- 2006-03-06 UA UAA200710934A patent/UA96412C2/ru unknown
- 2006-03-06 AU AU2006222500A patent/AU2006222500B2/en not_active Ceased
- 2006-03-06 WO PCT/CA2006/000315 patent/WO2006094385A1/en not_active Ceased
- 2006-03-06 JP JP2008500016A patent/JP2008531739A/ja active Pending
- 2006-03-06 NZ NZ577283A patent/NZ577283A/en not_active IP Right Cessation
- 2006-03-06 NZ NZ560840A patent/NZ560840A/en unknown
- 2006-03-06 CN CN201110306752.7A patent/CN102357104B/zh not_active Expired - Fee Related
- 2006-03-06 CN CN2006800075336A patent/CN101137748B/zh not_active Expired - Fee Related
- 2006-03-06 EP EP06705269A patent/EP1863906A4/en not_active Withdrawn
- 2006-03-06 RU RU2007137008/10A patent/RU2461630C2/ru not_active IP Right Cessation
- 2006-03-06 DK DK11174887.7T patent/DK2388315T3/da active
- 2006-03-06 MX MX2007010962A patent/MX2007010962A/es active IP Right Grant
-
2007
- 2007-08-20 IL IL185376A patent/IL185376A0/en unknown
-
2010
- 2010-08-04 US US12/850,599 patent/US20110195050A1/en not_active Abandoned
- 2010-09-07 IL IL208070A patent/IL208070A/en not_active IP Right Cessation
-
2012
- 2012-09-07 JP JP2012197457A patent/JP5674210B2/ja not_active Expired - Fee Related
- 2012-11-16 US US13/679,096 patent/US20130171106A1/en not_active Abandoned
-
2013
- 2013-10-09 US US14/049,737 patent/US9987315B2/en not_active Expired - Lifetime
-
2018
- 2018-05-07 US US15/972,994 patent/US20180256656A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2506085A (en) | Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV | |
| PL2155758T3 (pl) | Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka | |
| TW200732347A (en) | VEGF analogs and methods of use | |
| UA96412C2 (ru) | Применение комбинации вируса миксомы и рапамицина для лечения | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| TW200833662A (en) | 4,5-ring annulated indole derivatives and methods of use thereof | |
| TW200744618A (en) | Use of local immune suppression to enhance oncolytic viral therapy | |
| WO2008127710A3 (en) | Methods for treating cancer resistant to erbb therapeutics | |
| TW200833684A (en) | 5,6-ring annulated indole derivatives and methods of use thereof | |
| ATE363896T1 (de) | Gegen missbrauch gesicherte darreichungsform | |
| MY144616A (en) | Substituted dihydroquinazolines | |
| MX2010005107A (es) | Componente de silibinina para tratamiento contra hepatitis. | |
| MX2021008036A (es) | Bioplaguicidas para la enfermedad tizon tardio de la papa. | |
| MXPA05009526A (es) | Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica. | |
| MX2010004892A (es) | Terapia de combinacion para tratar infecciones virales persistentes. | |
| WO2007076161A3 (en) | Compounds with therapeutic activity | |
| MX2009012598A (es) | Formas de dosis que comprenden vx-950 y su regimen de dosificacion. | |
| WO2006078284A3 (en) | Methods and compositions related to antiviral therapy using algae and cyanobacteria | |
| HK1206984A1 (en) | Combination therapy of anti-mif antibodies and glucocorticoids | |
| SG155898A1 (en) | Treatment of diseases using nalmefene and its analogs | |
| WO2011091154A3 (en) | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth | |
| EP2021023A4 (en) | MYXOM VIRUS MUTANTS FOR CANCER TREATMENT | |
| HK1206985A1 (en) | Combination therapy of anti-mif antibodies and chemotherapeutics | |
| IN2011KN02819A (https=) | ||
| WO2008003514A3 (en) | Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |